Afatinib Malate Tablets 30?mg Jiyue
$1.00
Afatinib (brand: Jiyue) is a second?generation irreversible tyrosine kinase inhibitor targeting the ErbB family (EGFR/HER2/HER4), widely used in preclinical oncology and resistance mechanism studies. Each box contains seven 30?mg film?coated tablets. Produced by Zhejiang Zhidabimi (could be mismatch, using given manufacturer Chia Tai Tianqing Pharma, China), approved under China NMPA No.?H20203715, product code 86901523002468, barcode 6922096211228.
?? For laboratory research use only.?Please consult the staff for other purposes?
描述
Afatinib Malate Product Specifications
| Attribute | Details |
|---|---|
| Product Name | Afatinib Malate Tablets (Jiyue) |
| Generic Name | Afatinib (as malate salt) |
| CAS Number | 850140?72?6 |
| Molecular Formula | C??H??ClFN?O?·C?H?O? |
| Molecular Weight | ~972?g/mol (malate salt) |
| Dosage Form | Film-coated oral tablet |
| Strength | 30?mg per tablet |
| Pack Size | 7 tablets per box |
| Approval Number | H20203715 (China NMPA) |
| Product Code | 86901523002468 |
| Manufacturer | Chia Tai Tianqing Pharma Group Co., Ltd. |
| Barcode | 6922096211228 |
| Storage | Store at 20–25?°C, protect from light and moisture |
| Intended Use | Laboratory research only |
Afatinib Malate Mechanism of Action
Afatinib is an irreversible tyrosine kinase inhibitor of the ErbB family (EGFR/HER2/HER4) that blocks receptor phosphorylation, inhibiting downstream pathways (e.g., Ras/Raf/MEK/ERK, PI3K/Akt), suppressing tumor proliferation and inducing autophagy/apoptosis chemicalbook.com+12en.wikipedia.org+12selleckchem.com+12
Afatinib Malate Research Applications & Pharmacology
-
Oncology research: NSCLC, head & neck, breast cancer, investigating resistance mechanisms
-
Pathway studies: Analyze EGFR signaling, autophagy induction
-
Combination studies: With chemotherapy, radiotherapy, targeted agents
-
Preclinical dosing: ~20–60?mg/kg orally in rodents
-
Pharmacokinetics: Bioavailability ~92%, half-life ~37?hrs, ~95% protein-bound, metabolized not by CYP, excreted mainly fecal (85%) and urinary (4%)
Afatinib Malate Safety Profile & Side Effects
Common preclinical/clinical effects:
-
Rash, diarrhea, stomatitis, paronychia, fatigue
-
Hepatotoxicity (elevated ALT/AST in 20–50%, rare hepatic failure)
-
Pulmonary effects: dyspnea, rare interstitial lung disease
Handling & Storage:
-
Wear PPE, avoid dust/inhalation
-
Administer with sterile technique
-
Store at room temperature, dry, protected from light
-
Dispose according to hazardous pharmaceutical guidelines
?? Research?Use Disclaimer
This product is exclusively for laboratory research use. Not approved for diagnostic, therapeutic, or veterinary applications. Misuse may result in safety risks and unreliable outcomes.
其他信息
| 重量 | 1.1 公斤 |
|---|---|
| 尺寸 | 18 × 16 × 18 厘米 |
相关产品
-
Cetuximab NO1 Injection 100?mg/50?mL (Datalai) by Kelun Botai | EGFR?Targeted Biologic | Price comparison
Cetuximab NO1 Injection, 100?mg in 50?mL vial, is a biosimilar developed by Sichuan Kelun Botai Biopharma, branded as Datalai®. Approved in China (NMPA S20250006), this EGFR-targeting monoclonal antibody is ideal for laboratory or analytical research in oncology.
?? For laboratory research use only – Not for human consumption or therapeutic use. $1.00 -
Mechlorethamine Hydrochloride Injection (HaiPu®) – 1?mL:5?mg Vial Price Comparison
Mechlorethamine hydrochloride (HaiPu®) is a potent DNA-alkylating agent from the nitrogen mustard class, supplied as a 1?mL vial containing 5?mg. Manufactured by Shanghai Xudong Haipu Pharmaceutical Co., Ltd., with NMPA approval H31020897 and product code 86900808000625. Strictly for laboratory research use.?Please consult the staff for other purposes? $1.00 -
Temozolomide Capsules 100?mg × 5 – ChuanNuo (MySean) | Research Grade Glioblastoma Drug
Temozolomide 100?mg capsules, 5?count box, produced by Shanghai ChuanNuo Pharmaceuticals Co., Ltd., approved under NMPA H20234716. A key alkylating agent for glioblastoma and astrocytoma research—ideal for preclinical oncology models.
?? For laboratory research or analytical use only – Not for human consumption or therapeutic use. $1.00 -
Regorafenib Tablets (Reodixin®) – 40?mg
Regorafenib (Reodixin®) is an oral multi-kinase inhibitor targeting angiogenesis, proliferation, metastasis, and tumor immunity. FDA-approved for several advanced solid tumors. Here offered as 40?mg tablets in a 28-count bottle—strictly for laboratory research use only $1.00
评价
目前还没有评价